Apellis Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell APLS and other ETFs, options, and stocks.

About APLS

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE.

CEO

Cedric Francois

CEOCedric Francois

Employees

710

Employees710

Headquarters

Waltham, Massachusetts

HeadquartersWaltham, Massachusetts

Founded

2009

Founded2009

Employees

710

Employees710

APLS Key Statistics

Market cap

2.29B

Market cap2.29B

Price-Earnings ratio

-10.18

Price-Earnings ratio-10.18

Dividend yield

—

Dividend yield—

Average volume

2.01M

Average volume2.01M

High today

$18.27

High today$18.27

Low today

$17.73

Low today$17.73

Open price

$18.00

Open price$18.00

Volume

891.08K

Volume891.08K

52 Week high

$42.47

52 Week high$42.47

52 Week low

$16.10

52 Week low$16.10

APLS News

TipRanks 4d

Cautious Optimism: Apellis Pharmaceuticals’ Strategic Moves and Market Uncertainties Justify Hold Rating

Analyst Judah Frommer from Morgan Stanley maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) and increased the price target to $26.00...

Analyst ratings

59%

of 22 ratings

Buy

59.1%

Hold

40.9%

Sell

People also own

Based on the portfolios of people who own APLS. This list is generated using Robinhood data, and it’s not a recommendation.